These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 666596)

  • 1. Paradoxial response to dopaminergic agents in parkinsonism.
    Wiener WJ; Kramer J; Nausieda PA; Klawans HL
    Arch Neurol; 1978 Jul; 35(7):453-5. PubMed ID: 666596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Carbidopa-levodopa, growth hormone and parkinsonism].
    Marti-Masso JF; Carrera N; Martínez-Lage JM
    Rev Clin Esp; 1976 Jun; 141(6):525-32. PubMed ID: 968087
    [No Abstract]   [Full Text] [Related]  

  • 4. Lergotrile in the treatment of parkinsonism.
    Klawans HL; Goetz CG; Volkman P; Nausieda PA; Weiner WJ
    Neurology; 1978 Jul; 28(7):699-702. PubMed ID: 566868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 6. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
    Yahr MD; Clough CG; Bergmann KJ
    Lancet; 1982 Sep; 2(8300):709-10. PubMed ID: 6126641
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of parkinsonism.
    Calne DB; Teychenne PF; Pfeiffer RF
    Adv Exp Med Biol; 1977; 90():49-61. PubMed ID: 930750
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Parkinson's disease with lergotrile mesylate.
    Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M
    JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].
    Koziel H; Kuran W; Zakrzewska F
    Neurol Neurochir Pol; 1977; 11(1):73-80. PubMed ID: 840365
    [No Abstract]   [Full Text] [Related]  

  • 11. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
    [No Abstract]   [Full Text] [Related]  

  • 12. L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
    Glasgow GL; Henley JW; Willoughby EW
    Aust N Z J Med; 1974 Aug; 4(4):373-8. PubMed ID: 4278910
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical experience with the decarboxylase-blocked levodopa (Nacom) in the Parkinsonism patients].
    Völler GW; Deze J
    ZFA (Stuttgart); 1976 Mar; 52(7):380-8. PubMed ID: 773025
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS; Snider SR; Fahn S
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
    Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
    Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of levodopa, lergotrile, and bromocriptine on brain iron, manganese, and copper.
    Weiner WJ; Nausieda PA; Klawans HL
    Neurology; 1978 Jul; 28(7):734-7. PubMed ID: 566875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.